fgl2 prothrombinase is a newly discovered blood coagulation factor, mainly expressed in immune competent cells such as peripheral blood T lymphocytes,activated endothelial cells,and macrophages. It can initiate clotting reaction by directly activating prothrom-bin rather than relying on the classic intrinsic and extrinsic coagulation pathways. In recent years,with growing attention on the impor-tance of fgl2 prothrombinase,researches on it had penetrated into various clinical disciplines,which provided new directions for blocking or delaying the occurrence and development of diseases as well as for the development of new drugs. This would definitely bring new hopes for clinical prevention and treatment of diseases. Here,we reviewed recent basic researches on the clinical applications of fgl2 pro-tnromuinase in tne digestive,respiratory,urinary,cardiovascular,and rneumatoid immune systems,among otners,witn tne aim ol providing inspiration and reference for further studies in this field.%fgl2凝血酶原酶是新近发现的凝血因子,主要表达于外周血T淋巴细胞、活化的内皮细胞和巨噬细胞等免疫活性细胞,其不依赖经典内、外源性凝血途径,可直接激活凝血酶原,启动凝血反应.近年来随着对fgl2凝血酶原酶日益关注,相关研究渗透到临床各专业,为阻断、延缓疾病的发生、发展和新药开发提供了靶向,为防治疾病带来新希望.该文将近几年fgl2凝血酶原酶在消化、呼吸、泌尿、心血管及风湿免疫系统等的临床应用基础研究做一综述,作为研究者进一步深入探索的启发和参考.
展开▼
